On January 30, 2026, Elsevier, a world-renowned information analysis agency, officially announced the 2025 list of "China's Highly Cited Scholars".

2025 Year-End Review – Professor Zang Rongyu: "Hardcore Data" Validates the Value of Surgery, Chinese Standards Pave a New Journey for Ovarian Cancer Diagnosis and Treatment

2025 Year-End Review – Professor Li Li: From Norm Popularization to Precision Treatment, Reviewing the Annual Advances in Cervical Cancer Diagnosis and Treatment

Professor Di Wen, Research Fellow Yang Fan, Research Fellow Zhuang Guanglei, and other scholars from Renji Hospital, Shanghai Jiao Tong University School of Medicine, jointly published a landmark research achievement in Nature Biomedical Engineering (IF=26.6). The team independently developed a novel trispecific antibody, B7H3xCD3xPDL1, which innovatively integrates three core functions: tumor targeting, T cell activation, and immune microenvironment remodeling. Through a unique IFNγ-IL-15 positive feedback loop, the antibody successfully activates bystander T cells in the tumor microenvironment and reverses the immunosuppressive state, thereby providing an entirely new therapeutic approach for intractable solid tumors such as ovarian cancer and colorectal cancer. This groundbreaking achievement has garnered high recognition from the global academic community.

On January 12, the Beijing Municipal Medical Insurance Bureau and the Municipal Finance Bureau jointly issued the "Notice on Strengthening the Guarantee of Prenatal Examination Costs in Beijing" (hereinafter referred to as the "Notice"), which will comprehensively improve the level of prenatal examination cost protection for all types of medical insurance participants from January 1, 2026, actively support the construction of a fertility-friendly society, and promote high-quality population development. It mentioned that the reimbursement of prenatal examination medical expenses for three types of people, including flexible employment, retirees and insured residents, has attracted attention. Subsequently, "Beijing retirees can also be reimbursed for prenatal examinations" appeared on Weibo's hot search.

On November 28, 2025, the "2025 Tribute to Doctors Ceremony" jointly organized by the Global Times, Health Times and Life Times, a subsidiary of the People's Daily, released two lists: "Famous Doctors of the Country" and "Glorious Doctors". The "Tribute to Doctors" selection is a national non-news selection project for medical workers approved by the Office of the Party and the State Meritorious Service Honor and Commendation Working Committee.

On November 20, 2025, the final round of the 13th Surgical Video Competition hosted by Chinese Obstetrics and Gynecology Network (COGN) came to a successful end. Elite gynecological medical professionals from across the country gathered to make friends through the competition and exchange skills as the medium, presenting a medical exchange event that combines technical excellence with humanistic care. The competition attracted numerous industry peers to observe on-site, and the online live broadcast room was highly popular, jointly witnessing this pinnacle showdown that integrates professionalism and educational value.

Congratulations! Professor Zhu Lan Elected CAS Academician!

After intense voting, the results of the 5th China Obstetrics and Gynecology Network "Most Popular Hysteroscope/Laparoscope Brands Among Doctors" Selection are finally revealed! We sincerely thank every doctor colleague who participated in the voting. We are honored to announce the list of winners of this event (detailed at the end of the original article) and warmly invite the winning colleagues to contact us to receive their prizes as soon as possible. Next, let's uncover the brands that shone brightly and stood out in this selection!

The candidate list for the 2025 Prix Galien, hailed as the "Nobel Prize of Medicine," was recently announced, once again drawing attention to innovative achievements in the global biopharmaceutical field. In the field of cancer treatment, ovarian cancer has long been regarded as the "king of gynecological cancers" due to its high recurrence rate and mortality. However, recent breakthroughs in drug research targeting this disease have not only brought survival opportunities to patients but also promoted the practice and development of precision cancer treatment theory at the academic level, becoming an important microcosm of biopharmaceutical innovation.